Taking the mat is Judo Bio, an up-and-coming biotech armed with $100 million to develop oligonucleotide medicines targeting the kidney. Instructing Judo is CEO Rajiv Patni, M.D., an industry vet who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback